Join the club for FREE to access the whole archive and other member benefits.

Elastrin Therapeutics secures $10 million of funding for its calcification removal platform

07-Apr-2022

Key points from article :

Elastrin Therapeutics Inc. announced the closing of a $10 million funding round led by Kizoo Technology Capital.

Elastrin is a privately held biotechnology company developing therapeutics that render calcified tissue and organs supple again.

Other investors in the round include Starbloom Capital and SC Launch.

The company’s lead asset ELT-001 is an EDTA-loaded nanoparticle conjugated with a proprietary monoclonal antibody for the treatment of vascular calcification.

"Their technology is truly groundbreaking by not only delaying age-related disease but also reversing them.” - Frank Schueler, Managing Director of Kizoo Technology Capital.

Kizoo provides seed and follow-on financing with a focus on rejuvenation biotech.

Elastrin's underlying technology was developed by Dr. Naren Vyavahare over the last 20 years at Clemson University.

SC Launch, Inc. is an independent, non-profit corporation affiliated with SCRA (South Carolina Research Authority).

Starbloom Capital is a crypto-based family office that supports companies developing revolutionary longevity technologies.

Initially targeting stiffened arteries in cardiovascular disease, this could have wider implications

Mentioned in this article:

Tap on icon for description, click on resource name for more details.

Company

South Carolina-based biotech developing novel therapies

Company Representative

Managing Director of Kizoo Technology Capital

Company

Company providing financing and its focus is on rejuvenation biotech

Academic

Co-founder at TGenTech, Elastrin Therapeutics and Professor of Bioengineering at Clemson University